Efficacy and Safety of CyberKnife-Based SBRT and Linear Accelerator-Based IMRT/VMAT for Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Propensity Score-Matched Real-World Analysis
Technology in Cancer Research & Treatment · 2026
DOI: 10.1177/15330338261494457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2026. Verfasst von Shuo Sun und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Daping Hospital & Army Medical Center of PLA, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Radiosurgery, Lung Neoplasms, Radiotherapy, Intensity-Modulated. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Clinical Innovation Cultivation Fund of Army Medical Center of PLA, Science-Health Joint Medical Scientific Research Project of Chongqing.
Abstract (Originalsprache)
Introduction
CyberKnife-based stereotactic body radiotherapy (SBRT) has demonstrated favorable outcomes in multiple tumors. This study aimed to compare the efficacy and safety of CyberKnife-based SBRT versus linear accelerator (LINAC)-based IMRT/VMAT for thoracic radiotherapy in patients with non-small cell lung cancer (NSCLC) in a retrospective study.
Methods
In this retrospective cohort study, we retrospectively analyzed 461 NSCLC patients treated in our hospital. After propensity score matching (PSM), 138 patients (CyberKnife: 46; LINAC: 92) were matched. Median follow-up was 16.4 months (by reverse Kaplan-Meier method), and the short-term local control and early toxicity were compared.
Results
After PSM, baseline characteristics were well-balanced. No significant differences were observed in objective response rate ( P =0.838), disease control rate ( P =0.832), distribution of response categories ( P =0.972), or local progression-free survival (Log-Rank P =0.450). However, the CyberKnife group demonstrated superior safety. Symptomatic radiation pneumonitis (RP) (Grade≥2) was significantly lower (6.5% vs. 27.2%; OR=0.214, P =0.004). Notably, no Grade≥2 radiation esophagitis (RE) occurred in the CyberKnife group versus 18.5% with LINAC ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Center, Daping Hospital & Army Medical Center of PLA, Army Medical University, Chongqing, China.
- Department of Oncology, The 983rd Hospital of Joint Logistics Support Forces of the PLA, Tianjin, China.
- Radiobiology of Cancer Key Laboratory of Chongqing Education Commission of China, Chongqing, China.
ORCID-Profile: Mengxia Li
Förderung
- The Clinical Innovation Cultivation Fund of Army Medical Center of PLA
- Science-Health Joint Medical Scientific Research Project of Chongqing
Zitieren
APA
Sun, S., Duan, Y., Yang, G., Xiao, H., Chen, X., Wang, Z., Ma, J., Su, K., Chen, C., Tong, X., Xiong, Y., Yang, X., & Li, M. (2026). Efficacy and Safety of CyberKnife-Based SBRT and Linear Accelerator-Based IMRT/VMAT for Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Propensity Score-Matched Real-World Analysis. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338261494457
Vancouver
Sun S, Duan Y, Yang G, Xiao H, Chen X, Wang Z, et al. Efficacy and Safety of CyberKnife-Based SBRT and Linear Accelerator-Based IMRT/VMAT for Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Propensity Score-Matched Real-World Analysis. Technology in Cancer Research & Treatment. 2026. doi:10.1177/15330338261494457
BibTeX
@article{Sun2026,
author = {Sun, Shuo and Duan, Yi and Yang, Guannan and Xiao, He and Chen, Xiuqiong and Wang, Zhengbo and Ma, Jungang and Su, Kunpu and Chen, Chuan and Tong, Xueling and Xiong, Yanli and Yang, Xiao and Li, Mengxia},
title = {Efficacy and Safety of CyberKnife-Based SBRT and Linear Accelerator-Based IMRT/VMAT for Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Propensity Score-Matched Real-World Analysis},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
doi = {10.1177/15330338261494457}
}
EUVIMED